

## **PolyPid to Participate in Three Upcoming Fall Investor Conferences**

PETACH TIKVA, Israel, Sept. 03, 2024 — PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s management will participate in the following three investor conferences:

### **H.C. Wainwright 26<sup>th</sup> Annual Global Investment Conference**

PolyPid’s presentation will be available on-demand beginning on Monday, September 9, 2024, at 7:00 AM ET and throughout the conference, via the conference platform.

### **Lytham Partners Fall 2024 Investor Conference**

PolyPid’s fireside chat will be available on-demand beginning on Tuesday, October 1, 2024, via the conference platform and for 90 days thereafter on the Lytham investor portal.

### **Sidoti & Company Micro-Cap Virtual Conference**

Conference Date: November 13-14, 2024

The PolyPid management team will participate in one-on-one investor meetings during these events. Investors interested in meeting with PolyPid at the conferences should contact the appropriate conference directly.

### **About PolyPid**

PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matrix) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D- PLEX<sub>100</sub> is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.

For additional Company information, please visit <http://www.polypid.com> and follow us on Twitter and LinkedIn.

### **Contacts:**

PolyPid Ltd.

Ori Warshavsky

COO – US

908-858-5995

IR@Polypid.com

**Investors:**

Brian Ritchie

LifeSci Advisors

212-915-2578

[britchie@lifesciadvisors.com](mailto:britchie@lifesciadvisors.com)

